Concepedia

Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial

Mathias Rummel, Ulrich Kaiser, Christina Balser, Martina Stauch, Wolfram Brugger, Manfred Welslau, N. Niederle, Christoph Losem, Hans-Peter Boeck, Eckhart Weidmann,

The Lancet Oncology · 2015 · 153 citations · 17 references

DOI

Concepts

References

17

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

Jacques Ferlay, Isabelle Soerjomataram, Rajesh Dikshit et al. · International Journal of Cancer · 2014 · 29K citations · Full text

, , +16

A Predictive Model for Aggressive Non-Hodgkin's Lymphoma

New England Journal of Medicine · 1993 · 5K citations · Full text

, , +15

A predictive model for aggressive non-Hodgkin's lymphoma

Margaret A. Shipp, David P. Harrington, J R Anderson et al. · 1993 · 3.5K citations

, , +15

World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997

Nancy L. Harris, Elaine S. Jaffe, J Diébold et al. · Journal of Clinical Oncology · 1999 · 3.3K citations

, , +17

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Mathias Rummel, N. Niederle, Georg Maschmeyer et al. · The Lancet · 2013 · 1.5K citations

, , +6